The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
For the treatment of Superficial Femoral Artery
The product is expected to be launched in June 2023
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
India’s efforts are aimed at boosting health at the last mile
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes
The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
Subscribe To Our Newsletter & Stay Updated
